Lansoprazole (Makoprax, Proniz0r, Lozpras)
Lansoprazole
Macleods Pharmaceuticals SA (Pty) Ltd
Registration
- Applicant
- Macleods Pharmaceuticals SA (Pty) Ltd
- Registrations
- 6
Variants
| Product | Strength and form | Registration | Status | Schedule | Leaflets |
|---|---|---|---|---|---|
| Makoprax 15 MG capsules Each capsule contains LANSOPRAZOLE 15,0 mg | 15 MGCapsules | 52035852/11.4.3/0358 | Registered | Not determined | None |
| Makoprax 30 MG capsules Each capsule contains LANSOPRAZOLE 30,0 mg | 30 MGCapsules | 52035952/11.4.3/0359 | Registered | Not determined | None |
| Proniz0r 15 MG capsules Each capsule contains LANSOPRAZOLE 15,0 mg | 15 MGCapsules | 520360.35852/11.4.3/0360.358 | Registered | Not determined | None |
| Proniz0r 30 MG capsules Each capsule contains LANSOPRAZOLE 30,0 mg | 30 MGCapsules | 520361.35952/11.4.3/0361.359 | Registered | Not determined | None |
| Lozpras 15 MG capsules Each capsule contains LANSOPRAZOLE 15,0 mg | 15 MGCapsules | 520362.35852/11.4.3/0362.358 | Registered | Not determined | None |
| Lozpras 30 MG capsules Each capsule contains LANSOPRAZOLE 30,0 mg | 30 MGCapsules | 520363.35952/11.4.3/0363.359 | Registered | Not determined | None |
Regulatory status
This product is still scheduled by law even when this site could not determine which tier it falls under. The label carries the S number in a square border; ask a pharmacist if you need to know its schedule.
Listings for this ingredient that could not be applied to this product
S4: Lansoprazole
- except when intended for the temporary short-term relief of heartburn and hyperacidity, subject to:
- a maximum daily dose of 15 milligrams (S2); and
- a maximum treatment period of 14 days. (S2)
Consolidated Schedules 06 July 2026, lines 6854 to 6857
S2: Lansoprazole
- when intended for the temporary short-term relief of heartburn and hyperacidity, subject to –
- maximum daily dose of 15 milligrams
- maximum treatment period of 14 days. (S4)
Consolidated Schedules 06 July 2026, lines 2224 to 2228
This is an informational summary of the Medicines and Related Substances Act 101 of 1965 and its 2017 General Regulations. It is not medical advice and not legal advice. Always check the medicine's label, which carries the schedule number inside a square border, or ask a pharmacist if you are unsure.
2-[[3-Methyl-4-(2,2,2-trifluoroethoxy)-2-pyridinyl]methylsulfinyl]-1H-benzimidazole
Drag to rotate. Structure from PubChem CID 3883.
SAHPRA documents
SAHPRA has not published a professional information or patient information leaflet for this product.